Abbott study links CGM use in Type 2 diabetes patients on basal insulin to 45% lower 12-month mortality risk

By Public Technologies
  • Abbott flagged new real-world data linking continuous glucose monitoring use to fewer deaths in Type 2 diabetes patients on basal insulin.
  • Results will be presented at EASD starting Sept. 28, 2026, supporting broader adoption of Libre in a large insulin-treated population.
  • A separate observational analysis tied Libre use to fewer hospitalizations for acute diabetes events in Type 2 diabetes patients.
  • Abbott also plans to present additional FreeDM2 trial analyses showing faster, sustained improvements in glucose control following Libre 3 initiation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief on September 25, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.